Volume 8, Issue 2, December 2020, Page: 27-32
siRNA-dependent Gene Silencing of EVI1 Decreased Cell Proliferation in MKN45 Cells
Yuri Na, Albany Academy for Girls, New York, The United States of America
Hyejun Hwang, North London Collegiate School Jeju, Jeju, Republic of Korea
Jaehyuk Cho, Holy Cross High School, New York, The United States of America
Woo Rin Lee, Department Biological Science, University of Suwon, Hwaseong, Republic of Korea
Received: Sep. 14, 2020;       Accepted: Sep. 29, 2020;       Published: Oct. 16, 2020
DOI: 10.11648/j.cb.20200802.12      View  17      Downloads  13
Abstract
MDS1 and EVI1 complex locus protein EVI1 (MECOM) is an oncogenic transcription factor in many types of cancer. However, the clinical significance of MECOM in esophagogastric cancer has not been well elucidated. The aim of this study was to define the association of amplification of MECOM and esophagogastric cancer patients’ overall survival rate and to investigate the functional role of MECOM in MKN45 cell proliferation and apoptosis. In this study, a total of 3236 esophagus and gastric patients were analyzed from 16 genomic studies using cBioPortal, which provides an open-access resource with multiple cancer genomics data sets. When the patient samples were divided into two subgroups (MECOM amplified group and MECOM non-amplified group), the poor survival rate was significantly associated with MECOM amplification (p= 0.04). To investigate the role of EVI1 on esophagogastric cancer cells, siRNA dependent gene silencing of EVI1 in MKN45 cells was conducted. RT-PCR was used to examine the expression of EVI1 in MKN45 cells. The MTT assay was used to examine cell proliferation. The apoptotic cells were quantified by fluorescence cell counter. Knockdown of EVI1 leads to reduced cell proliferation and induced apoptosis in MKN45 cells. These results indicate that MECOM may be a potential target for esophagus and gastric cancer gene-targeted therapy. Collectively, our result suggested that EVI1 is a probable target gene for esophagogastric cancer cell proliferation.
Keywords
MECOM, Esophagogastric Cancer, siRNA, RT-PCR, Cell Proliferation, Apoptosis
To cite this article
Yuri Na, Hyejun Hwang, Jaehyuk Cho, Woo Rin Lee, siRNA-dependent Gene Silencing of EVI1 Decreased Cell Proliferation in MKN45 Cells, Cell Biology. Vol. 8, No. 2, 2020, pp. 27-32. doi: 10.11648/j.cb.20200802.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Khushalani N. Cancer of the esophagus and stomach. Mayo Clin Proc. 2008; 83: 712–722.
[2]
Leung WK, Wu M, Kakugawa Y, Kim JJ, Yeoh K, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008; 9: 279–287. doi: 10.1016/S1470-2045(08)70072-X.
[3]
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349: 2241–2252.
[4]
Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007; 17: 2–9.
[5]
Sayadi A, Jeyakani J, Seet SH, Wei CL, Bourque G, Bard FA, et al. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity. Oncogene. 2016; 35: 2311–2321.
[6]
Maicas M, Vázquez I, Alis R, Marcotegui N, Urquiza L, Cortés-Lavaud X, et al. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells. Biochim Biophys Acta Gene Regul Mech. 2017; 1860: 721–729.
[7]
Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007; 67: 3074–3084.
[8]
Soderholm J, Kobayashi H, Mathieu C, Rowley JD, Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia. 1997; 11: 352–358.
[9]
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: pl1.
[10]
Luesink M, Hollink IHIM, van der Velden VHJ, Knops RHJN, Boezeman JBM, de Haas V, et al. High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Blood. 2012; 120: 2064–2075.
[11]
Matsui A, Ihara T, Suda H, Mikami H, Semba K. Gene amplification: mechanisms and involvement in cancer. Biomol Concepts. 2013; 4: 567–582.
[12]
Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002; 62: 6240–6245.
[13]
Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, et al. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma. Cancer Sci. 2015; 106: 929–937.
[14]
Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer. 1996; 74: 1518–1525.
[15]
Queisser A, Hagedorn S, Wang H, Schaefer T, Konantz M, Alavi S, et al. Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene. 2017; 36: 1573–1584.
[16]
Tanaka M, Ishikawa S, Ushiku T, Morikawa T, Isagawa T, Yamagishi M, et al. EVI1 modulates oncogenic role of GPC1 in pancreatic carcinogenesis. Oncotarget. 2017; 8: 99552–99566.
[17]
Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411: 342–348.
[18]
Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, et al. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. Genes Chromosomes Cancer. 2016; 55: 375–388.
[19]
Zhu H, Gan X, Jiang X, Diao S, Wu H, Hu J. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019; 38: 163.
[20]
Zhang X-M, Liu Z-L, Qiu B, Xu Y-F, Pan C, Zhang Z-L. Downregulation of EVI1 expression inhibits cell proliferation and induces apoptosis in hilar cholangiocarcinoma via the PTEN/AKT signalling pathway. J Cancer. 2020; 11: 1412–1423.
[21]
Wu L, Wang T, He D, Li X, Jiang Y. EVI‑1 acts as an oncogene and positively regulates calreticulin in breast cancer. Mol Med Rep. 2018; 19: 1645–1653.
[22]
Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene. 2007; 396: 346–357.
[23]
Konantz M, André MC, Ebinger M, Grauer M, Wang H, Grzywna S, et al. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia. Leukemia. 2013; 27: 56–65.
[24]
Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, et al. Prominent oncogenic roles of EVI1 in breast carcinoma. Cancer Res. 2017; 77: 2148–2160.
[25]
Lu Y, Liang Y, Zheng X, Deng X, Huang W, Zhang G. EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemo-/radioresistance in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2019; 38: 82.
Browse journals by subject